An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication - Full Text View

An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication (INVOLVE)

This study has been completed.

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00577265

Purpose

An observational study to investigate how patients experience the ability to adjust their asthma maintenance medication according to instructions received from their physician. The primary aim is to create an insight in the perception of the patient when he has the ability to adjust his own maintenance treatment and how the patient exercises this in the daily practice.

Condition
Asthma

MedlinePlus related topics: Asthma

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective
Official Title:	An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication According to Instructions Received From Their Physician (AMD).

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

The primary aim is to create an insight in the perception of the patient when he has the ability to adjust his own maintenance treatment and how the patient exercises this in the daily practice.

Secondary Outcome Measures:

The secondary goal is to investigate the efficacy of the treatment with budesonide/formoterol AMD on the patients asthma control measured with the ACQ.

Study Start Date:

November 2004

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Inclusion Criteria: patients with prescription of budesonide/formoterol Turbuhaler 200/6 (adjustable maintenance dosing) and whom received instructions from their physician to adjust their asthma maintenance medication.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00577265

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:	Hannie de Munnik	AstraZeneca
Study Chair:	Monique Scholtes	AstraZeneca

More Information

Study ID Numbers:	S43
Study First Received:	December 18, 2007
Last Updated:	December 19, 2007
ClinicalTrials.gov Identifier:	NCT00577265
Health Authority:	Not required:

Keywords provided by AstraZeneca:

Asthma Control

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Respiratory Tract Diseases
Lung Diseases

Hypersensitivity, Immediate
Asthma
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Immune System Diseases
Bronchial Diseases

ClinicalTrials.gov processed this record on January 16, 2009